Pierre Moretti
Overview
Explore the profile of Pierre Moretti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aebischer-Gumy C, Moretti P, Brunstein Laplace T, Frank J, Grand Y, Mosbaoui F, et al.
MAbs
. 2024 Apr;
16(1):2342243.
PMID: 38650451
The controlled expression of two or more proteins at a defined and stable ratio remains a substantial challenge, particularly in the bi- and multispecific antibody field. Achieving an optimal ratio...
2.
Aebischer-Gumy C, Moretti P, Ollier R, Ries Fecourt C, Rousseau F, Bertschinger M
MAbs
. 2020 Jan;
12(1):1709333.
PMID: 31955651
We describe a mammalian expression construct (SPLICELECT™) that allows the redirection of a proportion of a secreted protein onto the cell surface using alternative splicing: whereas the majority of the...
3.
Aebischer-Gumy C, Moretti P, Little T, Bertschinger M
J Biotechnol
. 2019 Dec;
307:208.
PMID: 31826813
No abstract available.
4.
Aebischer-Gumy C, Moretti P, Little T, Bertschinger M
J Biotechnol
. 2018 Sep;
286:17-26.
PMID: 30172783
Cell populations that are exclusively composed by descendants from a defined single parental progenitor are referred to as "monoclonal", "clonal" or more correctly as "clonally derived cell population". Clonal derivation...
5.
Breton C, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al.
J Hematol Oncol
. 2014 Apr;
7:33.
PMID: 24731302
Background: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B...
6.
Hatlapatka T, Moretti P, Lavrentieva A, Hass R, Marquardt N, Jacobs R, et al.
Tissue Eng Part C Methods
. 2010 Dec;
17(4):485-93.
PMID: 21166520
First isolated from bone marrow, mesenchymal stem or stromal cells (MSC) were shown to be present in several postnatal and extraembryonic tissues as well as in a large variety of...
7.
Majore I, Moretti P, Stahl F, Hass R, Kasper C
Stem Cell Rev Rep
. 2010 Jul;
7(1):17-31.
PMID: 20596801
Up to 2.8 × 10(7) fibroblast-like cells displaying an abundant presence of mesenchymal stem cell (MSC) markers CD73, CD90, CD105 and a low level of HLA-I expression can be isolated...
8.
Tomala M, Lavrentieva A, Moretti P, Rinas U, Kasper C, Stahl F, et al.
Protein Expr Purif
. 2010 Apr;
73(1):51-7.
PMID: 20381622
Leukemia inhibitory factor (LIF) is a polyfunctional cytokine with numerous regulatory effects in vivo and in vitro. In stem cell cultures it is the essential media supplement for the maintenance...
9.
Moretti P, Hatlapatka T, Marten D, Lavrentieva A, Majore I, Hass R, et al.
Adv Biochem Eng Biotechnol
. 2009 Dec;
123:29-54.
PMID: 20012739
Mesenchymal stem or stromal cells (MSCs) have a high potential for cell-based therapies as well as for tissue engineering applications. Since Friedenstein first isolated stem or precursor cells from the...
10.
Majore I, Moretti P, Hass R, Kasper C
Cell Commun Signal
. 2009 Mar;
7:6.
PMID: 19302702
Background: A variety of cell types can be identified in the adherent fraction of bone marrow mononuclear cells including more primitive and embryonic-like stem cells, mesenchymal stem cells (MSC), lineage-committed...